| 1. |
Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol, 2015, 16(2): 200-207.
|
| 2. |
Cercek A, Roxburgh CSD, Strombom P, et al. Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and reponse in locally advanced rectal cancer. J Clin Oncol, 2017, 35: 15.
|
| 3. |
Pettersson D, L?rinc E, Holm T, et al. Tumour regression in the randomized StockholmⅢTrial of radiotherapy regimens for rectal cancer. Br J Surg, 2015, 102(8): 972-978.
|
| 4. |
Chiloiro G, Masciocchi C, van Soest J, et al. Surgical time to increase pCR in rectal cancer: pooled set of 3 078 patients from 7 randomized trials. Radioth Oncol, 2017, 123: S226-S227.
|
| 5. |
Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol, 2015, 16(8): 957-966.
|
| 6. |
Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer－the RAPIDO trial. BMC Cancer, 2013, 13: 279.
|
| 7. |
Tang Y, Jin J, Li S, et al. The initial results for a phase 3 study of short-term versus long-term chemoradiation therapy in locally advanced rectal cancer (STELLAR Trial). Int J Radiat Oncol Biol Phys, 2016, 96(2): S108-S109.
|
| 8. |
Kirk J, Gray WM, Watson ER. Cumulative radiation effect.Ⅰ. Fractionated treatment regimes. Clin Radiol, 1971, 22(2): 145-155.
|
| 9. |
Glimelius B, Graffman S, P?hlman L, et al. Preoperative irradiation with high-dose fractionation in adenocarcinoma of the rectum and rectosigmoid. Acta Radiol Oncol, 1982, 21(6): 373-379.
|
| 10. |
NCCN. NCCN clincial practive guidelines in oncoloy, rectal cancer version 3.0, 2017. 2017-03-13. http://www.nccn.org/.
|
| 11. |
Glynne-Jones R, Wyrwicz L, Tiret E, et al. ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl_4): iv22-iv40.
|
| 12. |
Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase Ⅲ study. Ann Oncol, 2016, 27(5): 834-842.
|
| 13. |
Marijnen C. For the cooperative group of the RAPIDO trial. Neoadjuvant chemoradiotherapy or 5×5 Gy followed by chemotherapy in rectal cancer: the RAPIDO trial. Radioth Oncol, 2017, 123: S227-S228.
|
| 14. |
Fan WH, Xiao J, An X, et al. Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer. J Cancer Res Clin Oncol, 2017, 143(8): 1461-1467.
|
| 15. |
Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys, 2008, 72(1): 99-107.
|
| 16. |
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
|
| 17. |
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg, 2006, 93(10): 1215-1223.
|
| 18. |
Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet, 2017, 390(10093): 469-479.
|
| 19. |
Sclafani F, Brown G, Cunningham D, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Br J Cancer, 2017, [Epub ahead of print].
|
| 20. |
Gollub MJ, Tong T, Weiser M, et al. Limited accuracy of DCE-MRI in identification of pathological complete responders after chemoradiotherapy treatment for rectal cancer. Eur Radiol, 2017, 27(4): 1605-1612.
|
| 21. |
Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol, 2005, 23(9): 1826-1838.
|
| 22. |
Pettit C, Walston JR, Wald PM, et al. Molecular profiling of rectal cancer identifies miRNAs associated with chemoradiation resistance and tumor progression. Int J Radiat Oncol Biol Phys, 2017, 99(2): S66-S67.
|
| 23. |
王屹, 陳功. 磁共振成像在直腸癌" 非手術治療”中的決策意義. 中華胃腸外科雜志, 2017, 20(6): 630-634.
|
| 24. |
Appelt AL, Pl?en J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol, 2015, 16(8): 919-927.
|
| 25. |
Burbach JP, den Harder AM, Intven M, et al. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol, 2014, 113(1): 1-9.
|
1/5
WeChat